Clinical Trial Update: Study To Evaluate The Safety And Efficacy of PBCLN-010 In Combination With PBCLN-014 in Participants Receiving Allogeneic Hematopoietic Cell Transplantation [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the safety and efficacy of PBCLN-010 in combination with PBCLN-014 in participants receiving allogeneic hematopoietic cell transplant…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancy

Drugs mentioned

• PBCLN-010
• PBCLN-014

Snippet

Sponsor: Prolacta Bioscience | Conditions: Hematologic Malignancy | Phase 2 | Status: TERMINATED